Collaborative Practice Sample Clauses

Collaborative Practice. A collaborative arrangement is an agreement between a registered dental hygienist working for a hospital and a licensed and registered dentist who has a formal relationship with the same hospital.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
Collaborative Practice. Dental hygienist can practice in any setting with collaborative agreement and can own or manage a collaborative dental hygiene practice. Dental hygienist must enter into a written agreement with one or more collaborative dentist(s) which must contain protocols for care. Dental hygienist must refer patients for annual dental exam. Requirements: Dental hygienist must have 2,400 hours of active practice in preceding 18 months or 3,000 hours in 2 of the past 3 years. Dentists may not collaborate with more than 3 dental hygienists. Provider Services: Collaborative practice dental hygienist can provide a dental hygiene assessment, radiographs, prophylaxis, fluoride treatments, assessment for and application of sealants, root planing, and may prescribe and administer and dispense topically applied fluoride and antimicrobials, depending on the specific services allowed in agreement with collaborating a dentist. New Mexico 2007 Sec. 61-5A-4-C‌ No supervision required for any dental hygienist to apply topical fluorides and remineralization agents in public and community medical facilities, schools, hospitals, long-term care facilities and such other settings as the board may determine. New York 2005
Sample 1Sample 2
Collaborative Practice. (a) Build innovative and sustainable primary and preventative health care models that promote integrated, patient centred care.
Sample 1Sample 2
Collaborative Practice. RNs may develop a unit collaborative practice committee, with the concurrence of nurse managers and appropriate physician(s) for the purpose of enhancing the working relationships and teamwork necessary to provide good patient care.
Sample 1
Collaborative Practice. ▪ Participate in shared decision making of care delivery with individuals, groups and members of the settlement teams, refugee health teams and General Practices. ▪ Recognise when to seek advice from other members of the general practice team or other health service providers, for example, Refugee Health Fellows about the care of individuals and groups ▪ Share information with the general practice team ▪ Participate in research in settlement and health outcomes Reporting, Systems and Analytics • Provide high quality concise and timely reports for (Board, Sub Committees, Executive, Program Manager, External parties). • Actively use and promote the use of DPV Health systems such as TRAK, eCase, VHIMS, MyBookings, ESS, e3, Gemba, Trim, Haplite and others • Continually review service/support provided to analyse success and areas of improvement Financials, Budgets, Targets, Funding • Ensure that all financial transactions are undertaken in line with approved DPV Health policy and delegations • Achieve targets / budgets for your (Directorate/Program/Team/Function) Culture, Engagement, Diversity – People Experience • Demonstrates behaviours aligned with DPV Health Values and Code of Conduct • Participate in regular supervision, annual work plans and annual performance reviews • Actively participate in all required training, inductions and development • Actively participate in and attend organisationally required meetings in a positive constructive manner. Offering balanced views and seeking solutions • Actively supports and demonstrates inclusive behaviour with a zero tolerance for any bullying, harassment and inappropriate conduct Health and Safety • Take reasonable care to ensure no risk of harm to self and others in the workplace. This includes immediately reporting any incidents, near miss, hazards and injuries. • Comply with relevant Occupational Health and Safety laws, standards, safe work practices, policies and procedures and attend all safety initiatives, improvements & training. • Demonstrate safe work behaviours and conducting work in accordance with our safety management system. Risk Management and Compliance – Quality and Accreditation • Ensure documentation supports both quality and department standards • Actively identify, monitor and manage areas of key risk and lead appropriate escalation and response • Actively monitor and improve the quality and safety of their care and services • Identify risks as they emerge and proactively addressed new and ...
Sample 1
Collaborative Practice. A. The Employer and Union agree that it is in the best interest of the Employer, Employees, and patients for Employees to maximize their level of practice. To the extent possible, the Employer shall encourage the utilization of Employees at the top of their license and scope of practice for their role, within the boundaries of approved clinical privileges, and with the goal of enhancing Employee autonomy.
Sample 1
Collaborative Practice. Incentive Program (GP’s) DOH shall provide funding for a Collaborative Practice Incentive Program for GP’s as outlined in Schedule “L” – Collaborative Practice Incentive Program (GP’s).
Sample 1
AutoNDA by SimpleDocs
Collaborative Practice. Dental hygienist can practice in any setting with collaborative agreement and can own or manage a collaborative dental hygiene practice. Dental hygienist must enter into a written agreement with one or more collaborative dentist(s) which must contain protocols for care. Dental hygienist must refer patients for annual dental exam. Requirements: Dental hygienist must have 2,400 hours of active practice in preceding 18 months or 3,000 hours in 2 of the past 3 years. Dentists may not collaborate with more than 3 dental hygienists. Provider Services: Collaborative practice dental hygienist can provide a dental hygiene assessment, radiographs, prophylaxis, fluoride treatments, assessment for and This document is intended for informational purposes only and does not constitute a legal opinion regarding dental practice in any state. To verify any information, please contact your state’s dental board. Revised August 2022 xxx.xxxx.xxx application of sealants, root planing, and may prescribe and administer and dispense topically applied fluoride and antimicrobials, depending on the specific services allowed in agreement with collaborating a dentist. New Mexico 2007 Sec. 61-5A-4-C‌ No supervision required for any dental hygienist to apply topical fluorides and remineralization agents in public and community medical facilities, schools, hospitals, long-term care facilities and such other settings as the board may determine. New York 2005
Sample 1
Collaborative Practice. Approaches Local Agreement component will: Include a definition of the role of community based child protection in active engagement and joint visits. Include a definition of the role of community based child protection in consultation/allocations meetings and documentation/recording requirements. Specify processes for where consent of the family has not been obtained (at each stage of the life of the case). Clearly articulate proactive engagement processes involving community based child and family services and community based child protection, including circumstances for making unannounced visits and proceeding without consent, as well as communication strategies. Specify agreed roles and responsibilities for child protection, community based child protection and integrated family services engaging hard to reach/hard to engage families to determine an appropriate service response both at referral phase and post allocation phase. Detail processes for recording and tracking, documenting evidence and responding to cumulative harm, based on a mutual understanding of cumulative harm. Detail local arrangements for working with Aboriginal Liaison worker/ACCO in working with Aboriginal children and families. Identify local processes to be followed in the establishment and management of care teams and agreed joint practice processes, such as monitoring, tasks and role clarification. Include agreed local strategies and contingency responses developed in relation to periods of heightened demand and/or limited available service capacity and of the expectations and communication processes relating to demand management or emerging demand-supply pressures. Include demand management processes that define the triggers which would signal an impending lack of capacity to undertake intake assessments or allocate to family services. Detail contingency responses that consider the roles and responsibilities of key partners, the management of child protection, community and professional referrals, self referrals and referrals about Aboriginal children. Articulate processes for informing child protection when demand strategies or contingency responses are being implemented. Mediation Process and Dispute Resolution In a highly integrated system comprising both statutory and non statutory services, robust advocacy and dialogue about a child’s best interests are necessary and encouraged. The key to building trust and relationships is a commitment to managing differences and resolvi...
Sample 1

Related to Collaborative Practice

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Research Use The Requester agrees that if access is approved, (1) the PI named in the DAR and (2) those named in the “Senior/Key Person Profile” section of the DAR, including the Information Technology Director and any trainee, employee, or contractor1 working on the proposed research project under the direct oversight of these individuals, shall become Approved Users of the requested dataset(s). Research use will occur solely in connection with the approved research project described in the DAR, which includes a 1-2 paragraph description of the proposed research (i.e., a Research Use Statement). Investigators interested in using Cloud Computing for data storage and analysis must request permission to use Cloud Computing in the DAR and identify the Cloud Service Provider (CSP) or providers and/or Private Cloud System (PCS) that they propose to use. They must also submit a Cloud Computing Use Statement as part of the DAR that describes the type of service and how it will be used to carry out the proposed research as described in the Research Use Statement. If the Approved Users plan to collaborate with investigators outside the Requester, the investigators at each external site must submit an independent DAR using the same project title and Research Use Statement, and if using the cloud, Cloud Computing Use Statement. New uses of these data outside those described in the DAR will require submission of a new DAR; modifications to the research project will require submission of an amendment to this application (e.g., adding or deleting Requester Collaborators from the Requester, adding datasets to an approved project). Access to the requested dataset(s) is granted for a period of one (1) year, with the option to renew access or close-out a project at the end of that year. Submitting Investigator(s), or their collaborators, who provided the data or samples used to generate controlled-access datasets subject to the NIH GDS Policy and who have Institutional Review Board (IRB) approval and who meet any other study specific terms of access, are exempt from the limitation on the scope of the research use as defined in the DAR.

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Research Program 2.1 University will use reasonable efforts to conduct the Research Program described in Attachment A which is hereby incorporated in full by reference (“Research Program”), and will furnish the facilities necessary to carry out said Research Program. The Research Program will be under the direction of _____________________ (“Principal Investigator”), or his or her successor as mutually agreed to by the Parties and will be con­ducted by the Principal Investigator at the University.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Research Project 3.1 These Materials and Data will be used by Recipient's PI solely in connection with the Research Project, as named and described in the attached research application (insert Research Project name below):

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Research Use Reporting To assure adherence to NIH GDS Policy, the PI agrees to provide annual Progress Updates as part of the annual Project Renewal or Project Close-out processes, prior to the expiration of the one (1) year data access period. The PI who is seeking Renewal or Close-out of a project agree to complete the appropriate online forms and provide specific information such as how the data have been used, including publications or presentations that resulted from the use of the requested dataset(s), a summary of any plans for future research use (if the PI is seeking renewal), any violations of the terms of access described within this Agreement and the implemented remediation, and information on any downstream intellectual property generated from the data. The PI also may include general comments regarding suggestions for improving the data access process in general. Information provided in the progress updates helps NIH evaluate program activities and may be considered by the NIH GDS governance committees as part of NIH’s effort to provide ongoing stewardship of data sharing activities subject to the NIH GDS Policy.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

Time is Money Join Law Insider Premium to draft better contracts faster.